• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

January 14, 2019
Company Drug/Device Medical Condition Status
Oppilan Pharma Ltd. OPL-002 inflammatory bowel disease (IBD) Phase I trial initiated enrolling 72 subjects
Pliant Therapeutics, Inc. PLN-74809 idiopathic pulmonary fibrosis Phase I trial initiated enrolling 90 healthy subjects
Deciphera Pharmaceuticals, Inc. rebastinib in combination with carboplatin advanced or metastatic solid tumors Phase Ib/II trial initiated enrolling 117 subjects (18 subjects in Part 1 and 99 subjects in Part 2)
Protagonist Therapeutics, Inc. PTG-300 beta thalassemia Phase II trial initiated enrolling 84 adolescent and adult subjects
Galapagos NV GLPG1690 systemic sclerosis (SSc, or scleroderma) Phase IIa trial initiated enrolling 30 subjects with diffuse cutaneous SSc
Urovant Sciences vibegron abdominal pain due to irritable bowel syndrome (IBS) Phase IIa trial initiated enrolling 200 female subjects
Seres Therapeutics, Inc. SER-287 active mild-to-moderate ulcerative colitis Phase IIb trial initiated enrolling 200 subjects
Pfizer, Inc. PF-06651600 moderate to severe alopecia areata Phase IIb/III trial initiated enrolling 660 subjects
NeuroBo Pharmaceuticals, Inc. NB-01 diabetic neuropathic pain Phase III trial initiated enrolling 717 adult subjects at 80 sites in the U.S.
Tivic Health Systems, Inc. ClearUP sinus pain due to allergic rhinitis (hay fever) 510(k) clearance granted by the FDA
StemCyte Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) spinal cord injury IND approval granted by the FDA
MicroVention, Inc. WEB Aneurysm Embolization System intracranial wide neck bifurcation aneurysms PMA approval granted by the FDA
Rainier Therapeutics, Inc. vofatamab advanced or metastatic urothelial cell carcinoma (bladder cancer) that is positive for FGFR3 mutation and/or fusion Fast Track Designation granted by the FDA
Grifols Erytra Eflexis blood grouping Approval granted by the FDA

 

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing